Higher baseline global leukocyte DNA methylation is associated with MTX non-response in early RA patients

Low-dose methotrexate (MTX) is the first-line therapy in early rheumatoid arthritis (eRA). Up to 40% of eRA patients do not benefit from MTX therapy. MTX has been shown to inhibit one-carbon metabolism, which ...

Source: Arthritis Research and Therapy - June 26, 2019 Category: Rheumatology Authors: Helen R. Gosselt, Bertrand D. van Zelst, Maurits C. F. J. de Rotte, Johanna M. W. Hazes, Robert de Jonge and Sandra G. Heil Tags: Research article Source Type: research